Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
Matti Aapro(Clinique de Genolier), Vicente Valero(The University of Texas MD Anderson Cancer Center), Carlos Camps(Universitat de València), Iwona Hus(Medical University of Lublin), Hartmut Link(Medizinische Hochschule Hannover), Mario Campone(Institut de Cancérologie de l'Ouest), Hans Tesch, John A. Glaspy(University of California, Los Angeles), Marco Danova(Azienda Socio Sanitaria Territoriale di Pavia), Robert Leonard(National Cancer Centre Japan), Sylvain Choquet(Sorbonne Université), Ralph V. Boccia(Center for Cancer and Blood Disorders), Thamer Sliwa(Hanusch Hospital)
Cited by 77
Related Papers
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k